Neuphoria Therapeutics (NEUP) Gains from Investment Securities (2022 - 2026)
Neuphoria Therapeutics (NEUP) reported Gains from Investment Securities of $116223.0 for Q1 2026, down 15.02% on a QoQ basis from $136770.0 in Q4 2025.
Neuphoria Therapeutics (NEUP) has 5 years of Gains from Investment Securities data on file, last reported at $116223.0 in Q1 2026.
- Quarterly Gains from Investment Securities changed N/A year-over-year to $116223.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $116223.0 (changed N/A YoY) and the FY2025 annual result came in at $91211.0, up 78.4% from the prior year.
- Gains from Investment Securities fell to $116223.0 in Q1 2026 per NEUP's latest filing, from $136770.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $56.6 million in Q2 2022 and bottomed at -$113503.0 in Q2 2024.
- The 5-year median for Gains from Investment Securities is $83538.5 (2024), against an average of $5.5 million.
- The widest annual swing landed in 2024, when Gains from Investment Securities tumbled 104.85%; it then surged 22584.26% in 2025.
- Tracing NEUP's Gains from Investment Securities over 5 years: stood at $56.6 million in 2022, then tumbled by 99.92% to $46265.0 in 2023, then gained by 9.92% to $50854.0 in 2024, then surged by 168.95% to $136770.0 in 2025, then declined by 15.02% to $116223.0 in 2026.
- Per Business Quant, the three latest NEUP Gains from Investment Securities figures stand at $116223.0 (Q1 2026), $136770.0 (Q4 2025), and $4.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Neuphoria Therapeutics | 28.35 Mn | 8.95 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 116,223.00 |
| Mar 31, 2026 | 116,223.00 |
| Dec 31, 2025 | 136,770.00 |
| Dec 31, 2025 | 136,770.00 |
| Sep 30, 2025 | 51,839.00 |
| Sep 30, 2025 | 51,839.00 |
| Jun 30, 2025 | 3.49 Mn |
| Jun 30, 2025 | 3.49 Mn |
| Mar 31, 2025 | 50,854.00 |
| Mar 31, 2025 | 50,854.00 |
| Dec 31, 2024 | 50,854.00 |
| Dec 31, 2024 | 50,854.00 |
| Sep 30, 2024 | 91,551.00 |
| Sep 30, 2024 | 91,551.00 |
| Jun 30, 2024 | 140,462.00 |
| Jun 30, 2024 | 140,462.00 |
| Mar 31, 2024 | -98,708.00 |
| Mar 31, 2024 | -98,708.00 |
| Dec 31, 2023 | 46,265.00 |
| Dec 31, 2023 | 46,265.00 |
| Sep 30, 2023 | -36,166.00 |
| Sep 30, 2023 | -36,166.00 |
| Jun 30, 2023 | 2.34 Mn |
| Jun 30, 2023 | 2.34 Mn |
| Jun 30, 2022 | 56.63 Mn |
| Jun 30, 2022 | 56.63 Mn |